• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Baloxavir reduces influenza viral load and duration of symptoms

byDayton McMillan
September 11, 2018
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 3 mins read
Vaccines for predicted influenza strains may provide wide protection [PreClinical]
Share on FacebookShare on TwitterShare on LinkedIn

1. The antiviral agent baloxavir (baloxavir marboxil) decreased duration of influenza symptoms significantly more than in patients treated with either placebo or oseltamivir.

2. Baloxavir reduced viral load significantly more 1 day after initiation of treatment than placebo or oseltamivir.

Evidence Rating Level: 1 (Excellent)     

Study Rundown: Emergence of viral strains resistant to traditional influenza antiviral agents has made development of novel agents a public health need. The agent baloxavir functions as a prodrug to a small molecule inhibitor of the influenza viral replication process. Animal studies using baloxavir have showed its efficacy in reducing both influenza viral load and associated mortality. This phase 2 and 3 study evaluated baloxavir in patients with acute uncomplicated influenza infection and showed the primary endpoint of time to alleviation of influenza symptoms was reduced in baloxavir patients relative to patients treated with placebo or oseltamivir. Viral load after 1 day of treatment was also found to be significantly reduced in the baloxavir group relative to the placebo or oseltamivir groups. Adverse events related to treatment were found at a higher rate in the oseltamivir compared to the baloxavir or placebo groups.

Strengths of this study include inclusion of patients from multiple countries, the randomized design of the phase 3 study, and the thorough profile of adverse events. Limitations include study of only generally healthy patients and study of patients without complicated or severe influenza cases.

Click to read the study in the NEJM (New England Journal of Medicine)

RELATED REPORTS

CDC reports increasing early-season influenza activity and at least 900 deaths nationwide

2MM: AI Roundup: NHS England expands Microsoft Copilot nationwide, ARPA-H advances autonomous cardiovascular AI, FDA advisors back Moderna’s mRNA influenza vaccine, and UpDoc earns first clearance for a patient-facing large language model

Relevant Reading: Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil

FDA approvedFor influenza: mFlusiva (Influenza Vaccine, mRNA), Aug 5, 2026→

In-Depth [randomized controlled trial]: These associated phase 2 and phase 3 trials enrolled patients between 2015 and 2017. Eligible patients had a fever, one or more respiratory symptoms, and symptoms lasting less than 48 hours. Patients were excluded if they had underlying conditions or were hospitalized for their illness. Symptoms were assessed on a standard scale and samples for influenza viral load were taken at standard time points. The primary outcome was time to alleviation of symptoms. For the phase 2 trial 400 patients were enrolled and 389 completed the study. Baloxavir was studied at doses of 10, 20, and 40mg and all doses lowered duration of symptoms compared to placebo (54.2, 51.0, 49.5, and 77.7 hours, respectively; P<0.05 for all baloxavir doses compared to placebo). Adverse events were reported in 23.0 to 27.0% of patients in the baloxavir dose groups and 29.0% of patients in the placebo group. The phase 3 trial had 1366 patients complete the trial and 1064 (n=456, 231, and 377 for baloxavir, placebo, and oseltamivir groups, respectively) were included in the intention-to-treat analysis as they were confirmed influenza positive. Influenza A(H3N2) infection was present in over 80% of patients in all trial groups. Median time to alleviation of symptoms was lower in baloxavir patients compared to placebo with both confirmed influenza infection (53.7 hours vs. 80.2 hours, P<0.001) and the general study population (65.4 hours vs. 88.6 hours, P<0.001). Both adolescents and adults experienced faster symptom alleviation with baloxavir. Baloxavir significantly reduced viral load 1 day after treatment initiation compared to both oseltamivir and placebo treated patients. Adverse events were found in 20.7, 24.6, and 24.8% of patients in the baloxavir, oseltamivir, and placebo groups, respectively.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: Baloxavirinfluenzaoseltamivir
Previous Post

Addition of CT angiography to standard care for stable chest pain reduces mortality due to coronary disease

Next Post

Lower patient satisfaction reported at for-profit dialysis centers

RelatedReports

The image features vials of a vaccine, a patient using a respiratory device, and medical devices highlighting aspects of infectious disease management, likely related to influenza.
2MM Trial Briefs

CDC reports increasing early-season influenza activity and at least 900 deaths nationwide

October 31, 2026
Collage of medical tech icons circling a central chip with 'AI Roundup' title and 2 Minute Medicine logo in teal background.
AI Roundup

2MM: AI Roundup: NHS England expands Microsoft Copilot nationwide, ARPA-H advances autonomous cardiovascular AI, FDA advisors back Moderna’s mRNA influenza vaccine, and UpDoc earns first clearance for a patient-facing large language model

September 3, 2026
Pain control after surgery collage: an older woman resting on a hospital pillow beside a teal nerve that branches at one end
Infectious Disease

Concomitant COVID-19 and influenza vaccination not linked to increased adverse events

June 29, 2026
Live attenuated vaccine less effective in recent influenza season
Emergency

Adjuvanted influenza vaccines and high-dose influenza vaccines may have similar effectiveness in adult patients

May 15, 2026
Next Post

Lower patient satisfaction reported at for-profit dialysis centers

2 Minute Medicine Rewind September 10, 2018

Use of piperacillin-tazobactam (Zosyn) likely less effective than meropenem for ceftriaxone-resistant gram-negative bacteremia

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • In a randomized sham-controlled trial, acupoint thread embedding produced a between-group difference in change from baseline of 1.8 kg at 12 weeks and 3.0 kg at 24 weeks in Chinese women with overweight or obesity
  • PROT-001 was generally safe and well tolerated in a phase 1 study of healthy volunteers with AL amyloidosis
  • 2MM: AI Roundup- PTSD Prediction, Gait as a Biomarker, Faster Cardiac MRI, and Perinatal Mental Health Chatbots [November 12th, 2026]
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.